February 11, 2021 01:41 PM EST

Vigene Biosciences goes big on Maryland viral vector expansion as it rides high on Altimmune vaccine deal

Conner Mitchell

Boosted by a gangbusters year for Rockville-based Emergent BioSolutions and its viral vectors for Covid-19 vaccines, the state of Maryland has continued to cement …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Vigene Biosciences goes big on Maryland viral vector expansion as it rides high on Altimmune vaccine deal

Conner Mitchell

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Vi­gene Bio­sciences goes big on Mary­land vi­ral vec­tor ex­pan­sion as it rides high on Al­tim­mune vac­cine deal

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Vigene Biosciences goes big on Maryland viral vector expansion as it rides high on Altimmune vaccine deal